Hutchmed licenses KRAS-EGFR antibody-conjugate therapy from GSK
Hutchmed (China) Limited announced an exclusive licensing agreement with GSK covering the KRAS-EGFR antibody conjugate cancer therapy, including HMPL-A830.
RNS Number: 2619T Hutchmed (China) Limited 03 September 2026 HUTCHMED Announces Licensing Agreement with GSK for KRAS-EGFR-Antibody Conjugate Cancer Therapy- Exclusive License for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate ("ATTC"), which is expected to enter cli…